ANDA 207774, held by Zydus Lifesciences. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 207774 (Doxycycline Hyclate), held by Zydus Lifesciences, was first approved by FDA on May 31, 2018, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 31, 2018 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 50MG BASE · capsule;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 100MG BASE · capsule;oral | Doxycycline Hyclate | Rx |
| Jul 25, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 5, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 31, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters